TMCnet News
Eleven Biotherapeutics to Present at Oppenheimer 25th Annual Healthcare ConferenceCAMBRIDGE, Mass. --(Business Wire)-- Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that Abbie Celniker, Ph.D., President and Chief Executive Officer, will present a company overview at the Oppenheimer 25th Annual Healthcare Conference in New York on Thursday, December 11, 2014 at 10:55 a.m. ET. A live webcast can be accessed from the Investors & Media section of Eleven's website at www.elevenbio.com. An archived replay of the webcast will be available on the Company's website for 7 days after the conference. About Eleven Biotherapeutics Eleven Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary protein engineering platform, called AMP-Rx, that it applies to the discovery and development of protein therapeutics to treat diseases of the eye. Eleven's therapeutic approach is based on the role of cytokines in diseases of the eye, the company's understanding of the structural biology of cytokines and the company's ability to rationally design and engineer proteins to modulate the effects of cytokines. Cytokines are cell signaling molecules found in the body that can have important inflammatory effects. |
